Relative Market Share
                                    According to the proponents of the BCG (Herndemson
                                    1972), It captures the relative market share of a business unit or product. But that is not all! It allows the analysed business
                                    unit be pitted against its competitors. As earlier emphasized above, this is due to the sometime correlation between relative
                                    market share and the product’s cash generation. This phenomenon is often likened to the experience curve paradigm that
                                    when an organisation enjoys lower costs, improved efficiency from conducting business operations overtime. The basic tenet
                                    of this postulation is that the more an organisation performs a task often; it tends to develop new ways in performing those
                                    tasks better which results in lower operating cost (Cipher 2006). What that suggests is that the experience curve effect requires
                                    that market share is increased to be able to drive down costs in the long run and at the same time a company with a dominant
                                    market share will inevitably have a cost advantage over competitor companies because they have the greater share of the market.
                                    Hence, market share is correlated with experience. 
                                    A case in point is Apple Computer’s flagship product called the iPod, which occupies a dominant 73% share the portable music player market (Cantrell
                                    2006). Analysts believe it is the impetus for Apple's financial rebirth 40% of Apple's sales is attributed to the iPod product
                                    line (Cantrell 2006). Similarly, Dell’s PC line shares the same market dominance theory as the iPod. The PC manufacture giant occupies a worldwide market
                                    share of 18.1%, which is commensurate to its large market revenue above its competitors (see figure 2). 
                                    Figure 2: Source: Reuters 2006
                                    
                                     
                                    Market Growth
                                    Market growth axis, correlates with the product
                                    life cycle paradigm, and predicates the cash requirement a product needs relative to the growth of that market. A fast growing
                                    market is generally considered attractive, and pulls a lot of organisation’s resources in an effort to increase gains.
                                    A case in point is the technological market widely consider by experts as a fast growing market, and tends to attract a lot
                                    of competition. Therefore, a product life cycle and its associated market play a key role in decision-making. 
                                     
                                    Cash Cows
                                    These products are said to have high profitability,
                                    and require low investment for the fact that they are market leaders in a low-growth market. This viewpoint is captured by
                                    the founders themselves thus: 
                                    The cash cows fund their own growth. They pay the
                                    corporate dividend. They pay the corporate overhead. They pay the corporate interest charges. They supply the funds for R&D. They supply
                                    the investment resource for other products. They justify the debt capacity for the whole company. Protect them (Henderson
                                    1976). 
                                    According to experts (Drummond & Ensor 2004;
                                    Kotler 2003; McDonald 2003), surplus cash from cash cow products should be channelled into Stars and Questions in order to
                                    create the future Cash Cows. 
                                     
                                    Stars
                                    Stars are leaders in high growth markets. They
                                    tend to/should generate large amounts of cash but also use a lot of cash because of growth market conditions. For example,
                                    Apple Computer has a large share in the rapidly growing market for portable digital music players (Cantrell 2006). 
                                     
                                    Question Marks 
                                    Question Marks have not achieved a dominant market
                                    position, and hence do not generate much cash. They tend to use a lot of cash because of growth market conditions. Consider
                                    Hewlett-Packard’s small share of the digital camera market, behind industry leader Canon’s 21% (Canon 2006). However, this is
                                    a rapidly growing market. 
                                     
                                    Dogs
                                    Dogs often have little future and are big cash
                                    drainers on the company as they generate very little cash by virtue of their low market share in a highly low growth market.
                                    
                                    Consider Pfizer’s Inspra (Gibson 2006): “Pfizer launched this drug in Q4 2003 and continues to pump money into this problem child, despite anaemic sales of roughly $40 million
                                    in the $2.7 billion heart-failure market dominated by Toprol-XL (metoprolol). It was thought to gain market share and become
                                    a star, and eventually a cash cow when the market growth slowed. But, according to industry’s experts, Inspra is likely
                                    to remain a dog, despite any amount of promotion, given its perceived safety issues and a cheaper, more effective spironolactone
                                    in the same Pfizer portfolio. Because Pfizer invested heavily in promotion early on with Inspra, the drug's earnings potential and positive cash flow is elusive at best.
                                    A portfolio analysis of Pfizer's cardiovascular franchise would suggest redeploying promotional spend on Inspra to up-and-coming stars like Caduet (amlodipine/atorvastatin)
                                    or torcetrapib to ensure those drugs reach their sales potential.”